DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Frontier
Pharma: Asthma Therapeutics – Cytokine and Kinase Targeted Small
Molecules and mAbs Increase Pipeline Diversity and Dominate
First-in-Class Innovation” drug pipelines to their offering.
Asthma is a chronic condition affecting the respiratory system, with
disease occurrence linked to both genetic and environmental factors. It
has significant global incidence and there is currently no cure.
Pharmacotherapeutic intervention aims to provide patients with an
increased level of disease control and reduce the severity of symptoms,
and a number of inhalational therapeutic options are available.
Current asthma treatment options are able to provide the majority of
patients with a sufficient level of…